Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
Shenxin Zeng, Wenhai Huang, Xiaoliang Zheng, et al.
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112981-112981
Closed Access | Times Cited: 153

Showing 1-25 of 153 citing articles:

Kinase drug discovery 20 years after imatinib: progress and future directions
Philip Cohen, Darren A.E. Cross, Pasi A. Jänne
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 7, pp. 551-569
Open Access | Times Cited: 737
Targeted protein degradation: mechanisms, strategies and application
Lin Zhao, Jia Zhao, Kunhong Zhong, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 352
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
Kai Tang, Yahong Wu, Yihui Song, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 243
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Zhenyi Hu, Craig M. Crews
ChemBioChem (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 148
Ubiquitin ligases: guardians of mammalian development
David A. Cruz Walma, Zhuoyao Chen, Alex N. Bullock, et al.
Nature Reviews Molecular Cell Biology (2022) Vol. 23, Iss. 5, pp. 350-367
Open Access | Times Cited: 106
Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications
Qian Zhong, Xina Xiao, Yijie Qiu, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 87
The state of the art of PROTAC technologies for drug discovery
Chao Wang, Cangxin Zheng, Han Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 235, pp. 114290-114290
Closed Access | Times Cited: 75
Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies
Xiumei Wu, Mengyun Xu, M. Geng, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 74
Strategies for designing proteolysis targeting chimaeras (PROTACs)
Shipeng He, Guoqiang Dong, Junfei Cheng, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 3, pp. 1280-1342
Closed Access | Times Cited: 69
Advancing Strategies for Proteolysis-Targeting Chimera Design
Minglei Li, Ying Zhi, Bo Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2308-2329
Closed Access | Times Cited: 42
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 15
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Xiaowei Huang, Fengbo Wu, Jing Ye, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2402-2427
Open Access | Times Cited: 13
Developments of CRBN-based PROTACs as potential therapeutic agents
Chao Wang, Yujing Zhang, Yudong Wu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113749-113749
Closed Access | Times Cited: 91
Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions
Jindi Huang, Liye Chen, Jiangxia Wu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16033-16061
Closed Access | Times Cited: 63
Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands
Hong‐Yi Zhao, Haipeng Wang, Yu-Ze Mao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 6, pp. 4709-4726
Closed Access | Times Cited: 49
Recent Advances in PROTACs for Drug Targeted Protein Research
Tingting Yao, Heng Xiao, Hong Wang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10328-10328
Open Access | Times Cited: 38
Importance of Three-Body Problems and Protein–Protein Interactions in Proteolysis-Targeting Chimera Modeling: Insights from Molecular Dynamics Simulations
Wenqing Li, Jiabin Zhang, Li Guo, et al.
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 3, pp. 523-532
Closed Access | Times Cited: 36
PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
Nuwayo Ishimwe Sincere, Krishnan Anand, Sumel Ashique, et al.
Molecules (2023) Vol. 28, Iss. 10, pp. 4014-4014
Open Access | Times Cited: 34
Applications and prospects of cryo-EM in drug discovery
Kongfu Zhu, Chuang Yuan, Yongming Du, et al.
Military Medical Research (2023) Vol. 10, Iss. 1
Open Access | Times Cited: 29
Antiviral PROTACs: Opportunity borne with challenge
Jinsen Liang, Yihe Wu, Ke Lan, et al.
Cell Insight (2023) Vol. 2, Iss. 3, pp. 100092-100092
Open Access | Times Cited: 27
Design, synthesis and biological evaluation of KRASG12C-PROTACs
Xiaoyi Zhang, Tong Zhao, Minghao Sun, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 78, pp. 117153-117153
Closed Access | Times Cited: 24
Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
Yujeong Moon, Seong Ik Jeon, Man Kyu Shim, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 411-411
Open Access | Times Cited: 20
PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: A review
Chao Wang, Yujing Zhang, Wanpeng Yu, et al.
International Journal of Biological Macromolecules (2024) Vol. 261, pp. 129864-129864
Closed Access | Times Cited: 6
Identification of PLK1-PBD Inhibitors from the Library of Marine Natural Products: 3D QSAR Pharmacophore, ADMET, Scaffold Hopping, Molecular Docking, and Molecular Dynamics Study
Nan Zhou, Chuangze Zheng, Huiting Tan, et al.
Marine Drugs (2024) Vol. 22, Iss. 2, pp. 83-83
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top